Found 371 clinical trials
A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants
Secondary objectives include evaluating the effect of mitapivat on electrocardiogram (ECG) parameters, including concentration-QT interval corrected for heart rate (C-QTc) analysis under fasted conditions. The study will include a 28-day screening period, four 7-day treatment periods. Participants will receive a follow-up telephone call within 28 (1) days after the last …
- 0 views
- 16 Feb, 2024
- 1 location
SubsTRate OxidatioN in Girls
In addition, subjective appetite will be measured throughout the assessment periods.
- 0 views
- 16 Feb, 2024
- 1 location
A Study of TTYP01 in Healthy Adult Subjects
In Part C, 12 healthy subjects will be enrolled to evaluate the effect of food on the PK of TTYP01 using a randomized, open-label, two-period cross-over design. Participants will be randomized into two groups and administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fed conditions …
- 0 views
- 05 Aug, 2020
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
This study will compare the effects on cardiorespiratory fitness (CRF) of aerobic exercise in different amounts (number of minutes/session) over different periods of time (number of weeks). Aerobic exercise is physical activity of light-to-moderate intensity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and …
- 0 views
- 05 Aug, 2020
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Part 2: Participants aged 12 < 18 will receive; Period A: Risankizumab or ustekinumab based on body weight followed by; Period B: Risankizumab or no treatment. Period C: Re-treatment with risankizumab (if needed).
- 0 views
- 05 Aug, 2020
A Study to Evaluate the Tolerance Efficacy and Pharmacokinetics of TQB3558 Tablets
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The study is divided into phase Ia and phase Ib. …
- 0 views
- 16 Feb, 2024
- 1 location
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
This is a Phase 1, single-dose, open-label, randomized, three-period, three-way crossover study in which healthy adult participants will receive three separate single-dose administrations of ASTX660 capsules under three different conditions.
- 0 views
- 16 Feb, 2024
- 1 location
tVNS in Long COVID-19
The purpose of this study is to compare two sets of stimulus parameters to determine the one that best improves the health-related quality of life of these patients over a period of 6-weeks. Patients using their assigned device for at least 30 of the 42 possible opportunities will receive the …
- 0 views
- 05 May, 2025
- 2 locations
![Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis](/media/imagery/9826.svg)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Participants will receive subcutaneous (SC) injections of risankizumab or placebo at Week 0 and Week 4 (Period A). Beginning Week 16 (Period B), both the groups will receive risankizumab and placebo at different intervals. Total treatment duration is 56 weeks.
- 0 views
- 16 Feb, 2024
- 35 locations
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
The main objectives of this trial are to evaluate the efficacy and safety of oral BI 1358894 compared to placebo over a 6-week treatment period in participants with Major Depressive Disorder (MDD) and with inadequate response to antidepressants (SSRI or SNRI) utilizing a decentralized clinical trial (DCT) model.
- 0 views
- 16 Feb, 2024
- 1 location